

HEBERFERON (COVID-19) PUBLICATIONS

- Binh T. Ngo, et al. The time to offer treatments for COVID-19. medRxiv 2020.05.27.20115238; doi: <https://doi.org/10.1101/2020.05.27.20115238>. Now published in Expert Opinion on Investigational Drugs doi: 10.1080/13543784.2021.1901883. Available in: <https://pubmed.ncbi.nlm.nih.gov/33721548/>.
- Esquivel-Moynelo I, et al. A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial. Annals of Antivirals and Antiretrovirals. 2021. DOI: 001-014. 10.17352/aaa.000010. Available in: https://www.researchgate.net/publication/353218561_A_combination_treatment_of_IFN-a2b_and_IFN-g_accelerates_viral_clearance_and_control_inflammatory_response_in_COVID-19_Preliminary_results_of_a_randomized_controlled_trial.
- Campa-Legra I, et al. Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding. J Biomed Res Environ Sci. 2021;2(12):1253-1266. doi: 10.37871/jbres1380. Available in: <https://www.jelsciences.com/articles/jbres1380.pdf>.
- Griffin D, et al. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS reviews. 2021;23. DOI: 10.24875/AIDSRev.200001261. Available in: <https://pubmed.ncbi.nlm.nih.gov/33556957/>.



HeberFERON